Stock Financial Ratios, Dividends, Split History

CERC / Cerecor Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.62
Volume49,600.00
Market Cap ($M)137.59
Enterprise Value ($M)150.60
Book Value ($M)24.58
Book Value / Share0.78
Price / Book5.57
NCAV ($M)-27.39
NCAV / Share-0.87
Price / NCAV-5.00
Share Statistics
Weighted Average Number Diluted Shares Outstanding Adjustment 344,794
Weighted Average Number Of Diluted Shares Outstanding 18,754,799
Weighted Average Number Of Shares Outstanding Basic 18,410,005
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 31,266,989
Common Shares Outstanding 31,379,778
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.43
Return on Assets (ROA)2.06
Return on Equity (ROE)57.49
Balance Sheet (mrq) ($M)
Assets65.36
Liabilities40.78
Quick Ratio0.67
Current Ratio0.91
Income Statement (mra) ($M)
Sales Revenue Goods Net1,910,403.00
Revenues27,813,137.00
Revenue From Grants624,569.00
Licenses Revenue25,000,000.00
Contracts Revenue278,165.00
Operating Income13.89
Net Income11.90
Earnings Per Share Diluted0.42
Earnings Per Share Basic0.42
Cash Flow Statement (mra) ($M)
Cash From Operations12.50
Cash from Investing-18.91
Cash from Financing-18.91
Identifiers and Descriptors
CUSIP15671L109
Central Index Key (CIK)1534120

Split History

Stock splits are used by Cerecor Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
CERC : Cerecor Stock Analysis and Research Report

2017-11-04 - Asif

Cerecor is a biopharmaceutical company that is developing innovative drug candidates to make a difference in the lives of patients with neurologic and psychiatric disorders. The company's lead drug candidate is CERC-301, which the company currently intend to explore as a novel treatment for orphan neurologic indications. The company also have two pre-clinical stage compounds, CERC-611 and CERC-406. The company's portfolio of product candidates is summarized below: CERC-301: Orphan Neurologic Diseases. CERC‑301 belongs to a class of compounds known as antagonists of the N‑methyl‑D‑aspartate, or NMDA, receptor, a receptor subtype of the glutamate neurotransmitter system that is responsible for controlling neurologic adaptation. The company believe CERC‑301 specifically blocks the NMDA receptor subunit 2B, or NR2B. Cerecor has conducted two Phase 2 studies with this drug candidate as a potential adjunctive treatment for major depressive disorders, or MDD, in which the company obs...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap

2018-06-27 seekingalpha
One candidate is at Phase 2, and the results are expected in first half of 2019. (205-3)

CUSIP: 15671L109